Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis
NCT01859390 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 73
Last updated 2017-07-14
Summary
The purpose of this study will be to evaluate the effects of a modified formulation of AquADEKs (AquADEKs-2) on markers of inflammation, antioxidant levels and oxidative stress.
Cystic Fibrosis (CF) is a disease that affects the organs in the body such as the lungs. Some of the damage to the lungs of CF patients may be caused by something called oxidant/antioxidant imbalance and oxidative stress.
Oxidation in the body is kind of what happens to an apple when it turns brown after being cut. And, just as a squeeze of lemon juice stops the oxidation of an apple, antioxidants can stop the rusting (or damage) inside our bodies by unstable oxygen molecules called free radicals. Free radicals can help fight off bacteria and viruses but too many of them do damage instead. Our bodies need antioxidants to keep things in balance so we have the right amount of free radicals.
Many CF patients also have trouble digesting food and absorbing nutrients like vitamins. Many of the vitamins we rely on are antioxidants, like vitamins A, D, E, K and beta-carotene. In some people with CF, even though they take multivitamins and pancreatic enzymes, they still have low amounts of antioxidants. The investigators are looking to see if taking more vitamins and antioxidants will help CF patients.
AquADEKs-2 is an investigational new drug (a drug that has not received approval by the Food and Drug Administration \[FDA\]). This research study is being done with the AquADEKs-2 compared to a control multivitamin. The study drug, AquADEKs-2 contains standard amounts of fat-soluble vitamins (A, D, E, K) that are contained in typical CF multivitamin supplements plus several antioxidants including beta-carotene, mixed tocopherols (different forms of vitamin E), coenzyme Q10 (CoQ10), mixed carotenoids (lutein, lycopene and zeaxanthin), and the minerals zinc and selenium. The control multivitamin contains standard amounts of vitamins A, B, D, E, and K without additional antioxidant supplementation.
Conditions
Interventions
- DRUG
-
AquADEKs-2
AquADEKs-2 contains standard amounts of fat-soluble vitamins (A, D, E, K) that are contained in typical CF multivitamin supplements plus several antioxidants including beta-carotene, mixed tocopherols (different forms of vitamin E), coenzyme Q10 (CoQ10), mixed carotenoids (lutein, lycopene and zeaxanthin), and the minerals zinc and selenium.
- DIETARY_SUPPLEMENT
-
control multivitamin
The control multivitamin contains standard (standard for CF multivitamin supplements) amounts of vitamins A, B, D, E, and K without added antioxidants.
Sponsors & Collaborators
-
Cystic Fibrosis Foundation
collaborator OTHER -
Yasoo Health
collaborator INDUSTRY -
University of Colorado, Denver
lead OTHER
Principal Investigators
-
Scott Sagel, MD, PhD · University of Colorado, Denver
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 10 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-06-30
- Primary Completion
- 2015-04-30
- Completion
- 2016-07-31
Countries
- United States
Study Locations
More Related Trials
-
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis
NCT00757848 ·Status: COMPLETED ·Phase: PHASE2
-
Eficacy of Long-term Suplementation With Docosahexaenoic Acid in Patients With Cystic Fibrosis
NCT01783613 ·Status: COMPLETED ·Phase: NA
-
Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis
NCT04166396 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis
NCT00812045 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation
NCT02875366 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations
NCT03000348 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of Immunonutrition on the Patients With Cystic Fibrosis
NCT02048592 ·Status: UNKNOWN ·Phase: PHASE4
-
A CFit Study - Baseline
NCT03234387 ·Status: TERMINATED
-
SD Cystic Fibrosis Study
NCT00605761 ·Status: COMPLETED ·Phase: PHASE1
-
COVID-19 Antibody Responses In Cystic Fibrosis
NCT04863573 ·Status: UNKNOWN
-
Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease
NCT00625612 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetics of Polymyxin B in Adult Patients With Cystic Fibrosis
NCT04335370 ·Status: COMPLETED
-
Acceptability, Feasibility and Preliminary Efficacy of CFWP to Treat Clinically Elevated Fatigue in Adults With CF
NCT04809207 ·Status: COMPLETED ·Phase: NA
-
Bacterial Gene Profiling to Predict Antibiotic Resistance During Cystic Fibrosis Pulmonary Exacerbations
NCT04341532 ·Status: COMPLETED
-
Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF)
NCT02690857 ·Status: COMPLETED ·Phase: PHASE2
-
e-Health Program to Prevent Exacerbations in the Cystic Fibrosis Population
NCT06313827 ·Status: RECRUITING ·Phase: NA
-
Evaluating Sensations of Breathlessness in Patients With Cystic Fibrosis
NCT01799642 ·Status: COMPLETED
-
Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished Children
NCT02128984 ·Status: COMPLETED ·Phase: NA
-
Phase II Study of Digitoxin to Treat Cystic Fibrosis
NCT00782288 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation
NCT06861413 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation
NCT01262352 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function
NCT01685801 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Safety and Tolerability of Inhaled Nitric Oxide to Subjects With Cystic Fibrosis
NCT01958944 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis
NCT02566044 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Parameters to Assess Response to Intra-Venous Antibiotic Treatment for Pulmonary Exacerbations in Cystic Fibrosis
NCT04016571 ·Status: COMPLETED